Completion of a single-center phase I study of the safety and pharmacokinetics of CPL207280

We have just completed a phase I study of safety and pharmacokinetics (part B) of an innovative therapy that could be used in the treatment of diabetes and metabolic diseases. The product was administered to approximately 32 healthy volunteers as tablets in ascending doses with single administration in the first part of the study and multiple administrations in the double-blind second part.

Due to the global COVID-19 epidemic, the study was conducted using instructions and procedures in line with the guidelines of the Ministry of Health, Sanitary-epidemiological station, WHO (World Health Organization) and EMA (European Medicines Agency).

The tested compound belongs to the newest generation of drugs used in the treatment of diabetes and metabolic diseases. The study confirmed that the drug has a very good safety profile in toxicological and preclinical studies, unlike other drugs in this class. In the case of normal blood glucose levels, the drug does not lower the glucose level, which prevents the occurrence of hypoglycemia.

 The results of the study confirmed that the new therapy is effective in regulating blood glucose levels and could be used in the treatment of diseases such as type II diabetes.

Go back

News

GCLP accreditation

We are proud to announce that on February 2019 we have received a GCLP certificate which confirms our high quality of services.

Read more …

Christmas wishes

To all our Sponsors, Vendors, Employees and Co-Workers we wish joy and happiness for the in-coming Christmas!

Read more …

Privacy Policy introduced on 25th of May 2018

On May 25, 2018, the European Union will begin to enforce more strict privacy rules under the General Data Protection Regulation (GDPR), so we have introduced new Privacy Policy.

Read more …

International Clinical Trials Day on 24th of May 2018

Our Team has participated in one of the most importants conferences regarding Clinical Trials in Poland.

Read more …

New article about EMA guidelines on FIH studies

In "Scientific Publications" tab you can find an interesting, new article about update of EMA guideline on strategies to identify and mitigate risks for first-in-human clinical trials

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2022 © Bio Research Group. All rights reserved.

 

scroll to top ▲